Department of Medicine
Yale University School of Medicine
New Haven, Connecticut
Barbara Ann Burtness, MD, has disclosed that she has received consulting fees from AstraZeneca, Bristol-Myers Squibb, Genentech, IDDI, and Merck.
Division of Cancer Medicine
Department of Thoracic/Head and Neck Medical Oncology
The University of Texas MD Anderson Cancer Center
Maura L. Gillison, MD, PhD, has disclosed that she has received consulting fees from Aspyrian Therapeutics, Inc., Bristol-Myers Squibb, EMD Serono, and Merck.
John E. Ultmann Professor
Chairman, Department of Medicine
University of Chicago Medical and Biologic Sciences
Everett Vokes, MD, has disclosed that he has received consulting fees from AbbVie, Amgen, Ariad, AstraZeneca, Bayer, Biolumina, Boehringer Ingelheim, Bristol-Myers Squibb, Celgene, Eli Lilly, EMD Serono, Genentech, Leidos, Merck, Novartis, Regeneron, Takeda, and VentiRx and funds for research support from AbbVie and Bristol-Myers Squibb.
Megan Cartwright, PhD, has no real or apparent conflicts of interest to report.
Krista Marcello, has no real or apparent conflicts of interest to report.
Editorial Director, Hematology/Oncology
Kevin Obholz, PhD, has no real or apparent conflicts of interest to report.
Senior Managing Editor
Timothy A. Quill, PhD, has no real or apparent conflicts of interest to report.
This activity is intended for medical oncologists, radiation oncologists, surgical oncologists, and head and neck surgeons who care for patients with head and neck squamous cell carcinoma.
This program has been made available online.
Watch a CME/CE-certified Webcast of an ASCO 2018 symposium where John L. Marshall, MD, leads an expert panel reviewing the top 10 oncology biomarkers.
Expert commentary from Manish A. Shah, MD, on recent developments in targeting cancer stem cells in gastrointestinal cancers, including data from ASCO 2018.
Immune checkpoint inhibitors (ICIs) have expanded treatment options for patients who cannot tolerate chemotherapy. Read my thoughts on using ICIs in clinical practice, as well as some of the most promising salvage strategies for patients who progress on them.
Results from KEYNOTE-042 trial of first-line pembrolizumab vs standard chemotherapy in advanced NSCLC with PD-L1 TPS ≥ 1% from ASCO 2018 reported by Clinical Care Options (CCO).
You are accessing CCO's educational content today as a Guest user.
If you would like to continue with free, full access to the CCO Web sites, including free CME/CE credits, please click the button below.